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model was adjusted. Diabetics and non-diabetics were analysed
separately. Data on effectiveness of 12 month treatment were
taken from RIO-Diabetes (overweight/obese patients with
T2DM) and RIO-Europe (overweight with co-morbidities/obese
patients, without T2DM), respectively. Cost data were derived
from published sources for the year 2006 using €2.39 as daily
costs of rimonabant. A time horizon of 40 years and a discount
rate of 3% were applied. Input model data were varied plus/
minus 20% performing sensitivity analyses. RESULTS: The
model shows that adding rimonabant to diet and exercise, in
patients with BMI 30 kg/m2, or BMI >27 kg/m2 and additional
risk factors leads to an increased life expectancy as well as an
improved quality of life. Costs per LYG were €12,322 (diabetics)
and €46,966 (non-diabetics). Costs per QALYG were €8,788
(diabetics) and €12,590 (non-diabetics). Considering the interna-
tionally utilized threshold of €50,000 per QALYG, the treatment
with rimonabant can be assessed as cost-effective. The robustness
of this result was substantiated through sensitivity analyses.
CONCLUSION: Based on the results of the Rainbow model,
treating patients with rimonabant in combination with diet and
exercise is associated with a beneﬁt in effectiveness at acceptable
costs from a SHI-perspective, compared to a modiﬁcation of
lifestyle alone.
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OBJECTIVES: To perform a cost-effectiveness analysis of irbe-
sartan for the management of nephropathy in patients with
hypertension, type-2 diabetes and microalbuminuria in the
Mexican scenario. METHODS: The treatment of patients was
simulated with early irbesartan, 300 mg daily (initiating in the
microalbuminuria stage) and late irbesartan (initiating in the
stage of manifest nephropathy). These strategies were compared
with a control, consisting of standard anti-hypertensive therapy.
The progression of microalbuminuria to nephropathy, increase
to the doubling of serum creatinine, end stage renal disease
(ESRD) to death, was simulated over a temporary horizon of 20
years, using a Markov model previously published and adapted
to the Mexican scenario. The transition probabilities were based
in the study named Irbesartan in Reduction of Micro-
albuminuria-2, and the study called Irbesartan in Diabetic
Nephropathy Trial, and local sources. The costs and clinical
outcomes were discounted to an annual rate of 3%, and the
perspective of the public health care institutions in Mexico.
RESULTS: With early irbesartan there was a gain of 539.1 years
of life per 1000 treated patients, and with late irbesartan there
was a gain of 131.1, both compared to control. After 20 years
of treatment, early irbesartan prevented 87 cases of ESRD per
1000 patients treated, and late irbesartan prevented 54, both
compared to control. The cost per life-year gained with early
irbesartan was €22,998.93 and the cost per year free from
ESRD with late irbesartan was €11,503.94. The sensitivity
analysis showed that therapy with irbesartan is still cost-
effective compared to conventional antihypertensive treatment
after modifying various plausible assumptions. CONCLUSION:
The addition of irbesartan to conventional antihypertensive
therapy demonstrated an improvement in life expectancy and
reduction in the years with ESRD. It represented a cost-effective
option compared to control, which means greater efﬁciency in
the treatment of hypertension patients with type-2 diabetes and
microalbuminuria in Mexico.
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OBJECTIVES: Acute decompensated heart failure (AHF) is life-
threatening and a frequent cause of hospitalization for older
persons. The SURVIVE randomized controlled trial compared
levosimendan (levo) versus dobutamine (dob) with 180-day
mortality as primary endpoint. All-cause mortality at 31 days
was levo 12% and dob 14% (hazard ratio 0.85, p = 0.29) with
a similar differential at 180 days (HR 0.91, p = 0.40). Presented
here is the SURVIVE economic analysis. METHODS: SURVIVE
was conducted in Russia, Poland, France, Israel, Finland, UK,
Latvia, Germany, and Austria. Enrolled patients (N = 1327)
required IV inotropic support after insufﬁcient response to IV
diuretics or vasodilators. Case report forms (CRFs) documented
study drug administration, inpatient days (ICU, routine care),
procedures (e.g., PTCA, CABG, ICD), and safety data, during
initial admission. CRFs also described subsequent admissions
during follow-up. Hospital cost was calculated according to
length of day and procedures. Source of cost data was national
hospital payment schedules for France, Germany, and UK. Cost
for levo was not included in base case analysis. Cost-
effectiveness analysis used average market price for levo with
post-trial survival projected per published AHF methodology.
RESULTS: Length of stay (days) during initial admission was
identical (levo 14.4, dob 14.5, p = 0.96). During follow-up
similar patterns were observed for number of hospital admis-
sions (levo 0.7, dob 0.9, p = 0.25) and total hospital days (levo
11.5, dob 12.4, p = 0.46). Mean cost of initial hospital admis-
sion was similar (levo €5060, dob €4945, p = 0.91) as was total
hospital cost for the complete trial episode (levo €5471, dob
€5273, p = 0.93). Incremental cost per life year gained for levo
relative to dob was less than €27,000 with greater than 50%
likelihood. CONCLUSION: In SURVIVE hospital resource use
and costs were similar for levo and dob. Based on the survival
difference, levo is cost-effective relative to dob using accepted
benchmarks.
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OBJECTIVES: To assess the cost per quality-adjusted-life-year
(QALY) of Atorvastatin 10 mg (ATV) + Amlodipine 5/10 mg
(AML) compared with Atenolol 10 mg (ATE) + ATV, in hyper-
tensive patients with no history of coronary heart disease (CHD)
with normal to mildly elevated cholesterol and with at least 3
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